IMUC - ImmunoCellular Therapeutics, Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0356
+0.0024 (+7.25%)
At close: 3:49PM EDT
Stock chart is not supported by your current browser
Previous Close0.0332
Open0.0290
Bid0.0000 x 900
Ask0.0000 x 3000
Day's Range0.0290 - 0.0440
52 Week Range0.0120 - 0.2300
Volume656,733
Avg. Volume145,709
Market Cap1.492M
Beta (3Y Monthly)2.63
PE Ratio (TTM)N/A
EPS (TTM)-0.2690
Earnings DateAug 24, 2017 - Aug 25, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • PR Newswire

    ImmunoCellular Therapeutics Announces Completion of Asset Purchase Transaction with Private Biotechnology Company

    LOS ANGELES, Aug. 28, 2019 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (IMUC) today announced receipt of payment of $500,000 in conjunction with the completion of a transaction for the purchase of substantially all of ImmunoCellular's remaining assets, including its preclinical and clinical programs, technology, intellectual property and know-how. The first upfront payment of $500,000 was received by ImmunoCellular upon the initial closing of the asset sale transaction on May 8, 2019, and was non-refundable. The second, or continuation, payment of $500,000, which has been received, was dependent upon the satisfactory outcome of certain discussions between the Purchaser and the US Food and Drug Administration.

  • GlobeNewswire

    ImmunoCellular Therapeutics: Notice of Proposed Settlement of Derivative Action

    ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (IMUC), today issued the following announcement. ALL OWNERS OF IMMUNOCELLULAR THERAPEUTICS, LTD. (“IMMUNOCELLULAR” OR THE “COMPANY”) COMMON STOCK (TICKER SYMBOL: IMUC) AS OF JULY 24, 2019, WHO CONTINUE TO OWN SUCH SHARES (“CURRENT IMMUNOCELLULAR STOCKHOLDERS”).

  • PR Newswire

    ImmunoCellular Therapeutics Announces Asset Purchase Agreement with Private Biotechnology Company

    LOS ANGELES, July 16, 2019 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (IMUC), today announced an agreement with a privately held biotechnology company (the "Purchaser") for the purchase of substantially all of ImmunoCellular's remaining clinical and pre-clinical assets, including its preclinical and clinical programs, technology, intellectual property and know-how. ImmunoCellular's therapeutic assets are comprised of ICT-107 (phase 3-ready for glioblastoma), ICT-121 (phase 1 completed for recurrent glioblastoma) and ICT-140 (phase 1/2-ready for ovarian cancer), each of which is a patient-specific dendritic cell-based immunotherapy targeting solid tumors.

  • PR Newswire

    ImmunoCellular Announces Receipt of Notice of Noncompliance with The NYSE American Continued Listing Standards

    LOS ANGELES, Oct. 17, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced that on October 16, 2018, the Company received notice from the NYSE American LLC ("NYSE American" or the "Exchange") that it has determined to commence proceedings to delist the Company's Common Stock (NYSE American: IMUC) and Listed Common Stock Warrants (NYSE American: IMUC.WS) from the Exchange. Trading in the Company's securities on NYSE American has been suspended.

  • PR Newswire

    ImmunoCellular Therapeutics Announces Delisting and Deregistration of Common Stock and Listed Common Stock Warrants

    LOS ANGELES, Oct. 15, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today notified the NYSE American of its intention to voluntarily withdraw its Common Stock (NYSE American: IMUC) and Listed Common Stock Warrants (NYSE American: IMUC.WS) from listing on the NYSE American. ImmunoCellular intends to file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), with the Securities and Exchange Commission (the "SEC") on or about October 25, 2018.